Company / PP&E (Net)
Regeneron Pharmaceuticals PP&E (Net) History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$3.8B
FY2022
5-year range
$3.5B / $3.8B
FY2018-FY2022
Trend
+8.1%
vs FY2021
Sector context
#10 of 193
Health Care
What the data says
Among 193 Health Care companies, Regeneron Pharmaceuticals is in the top 5% for pp&e (net). PP&E (Net) has increased for 5 consecutive years, from $2.1B in FY2016 to $3.8B in FY2022.
Based on SEC 10-K filings.
$3.8B in FY2022 with a 5-year CAGR of +9.8%. Top quartile in the Health Care sector.
Improved from $3.2B to $3.8B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +9.8%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 193This company $3.8B Sector average $777.6M
▼
+383.9% above sector average
Key checks
Key Insights
- 5-year CAGR of +9.8%, indicating consistent growth.
- In FY2022, pp&e (net) increased 8.1% year-over-year.
- Ranks #10 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $3.8B | +8.1% |
| FY2021 | $3.5B | +8.1% |
| FY2020 | $3.2B | - |
| FY2019 | - | - |
| FY2018 | $2.6B | +9.2% |
| FY2017 | $2.4B | +13.2% |
| FY2016 | $2.1B | +30.7% |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026